Latest Sirolimus Stories
Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.
DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial.
Researchers from Baylor College of Medicine have provide the first direct genetic evidence that a complex of proteins known as mammalian target of rapamycin complex 1 (mTORC1) plays a crucial role in memory formation.
Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol â€“ a compound found in red wine â€“ when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone.
Test monitors level of a drug that helps prevent kidney rejection SILVER SPRING, Md., Feb. 11, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients.
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center.
A systematic review of medical evidence has determined drug-eluting stents (DES) outperform bare metal stents (BMS) for revascularization of chronic total occlusions.
HONG KONG, Jan.
Resveratrol, a compound in grapes, displays antioxidant and other positive properties.
FT. LAUDERDALE, Fla., Jan. 4, 2011 /PRNewswire/ -- OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology. The patent (U.S. Pat. No.